Results 301 to 310 of about 120,861 (346)

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Clinical Medicine Insights: Gastroenterology, 2012
Cheryl Durand, Kristine C. Willett, Alicia R. Desilets   +2 more
doaj  

Refractory Diarrhea After Dor Fundoplication: The Long-Term Impact of Proton Pump Inhibitor Therapy. [PDF]

Cureus
Mangum K, Bazemore M, Sandoval J, Kragh N, Soliman B.   +4 more
europepmc   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proton Pump Inhibitors

Annals of Pharmacotherapy, 2016
Objective: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. Data Sources: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole ...
Evan W, Colmenares, Ashley L, Pappas
  +6 more sources

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Proton pump inhibitors

Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
openaire   +3 more sources

Proton Pump Inhibitors

Reactions Weekly, 2017
Guidelines generally recommend proton pump inhibitors (PPIs) over histamine type 2 receptor antagonists when acid suppression is advocated because of a longer duration of action, a superior ability in reducing acid secretion, and the absence of tachyphylaxis with repeated dosing.
Licia Pensabene, Geoffrey Davidson
openaire   +2 more sources

Proton pump inhibitors

BMJ, 2023
Danny, Jenkins, Ines, Modolell
openaire   +2 more sources